Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18372890 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDPOLBMBOAT4 | |
| SCHEMBL10909304 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDENPP1 | |
| SCHEMBL4425907 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDPOLBMBOAT4 | |
| SCHEMBL20266759 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDPOLBMBOAT4 | |
| SCHEMBL22004819 | 0.79 | TP53 (0.45) | ALDH1A1KDM4EHPGDPOLBMBOAT4 | |
| SCHEMBL9680379 | 0.76 | KDM4E (0.46) | ALDH1A1KDM4EHPGDPOLBSMN1; SMN2 | |
| SCHEMBL864946 | 0.73 | ALDH1A1 (0.67) | ALDH1A1KDM4EHPGDGAAENPP1 | |
| SCHEMBL18358261 | 0.72 | PDE2A (0.42) | ALDH1A1KDM4EHPGDMBOAT4GAA | |
| SCHEMBL5332533 | 0.71 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDPOLBGAA | |
| SCHEMBL11054396 | 0.69 | KDM4E (0.62) | ALDH1A1KDM4EHPGDPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2017000277-A1 | SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017003894-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE3A, PDE4D | ALDH1A1 1376/4885KDM4E 2962/4885HPGD 167/4885 |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | PDE2A, PDE3A, PDE4D | ALDH1A1 1376/4885KDM4E 2962/4885HPGD 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.